Results 11 to 20 of about 3,908,577 (301)

Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas

open access: yesFrontiers in Immunology, 2021
These last 20 years, research on immune tumor microenvironment led to identify some critical recurrent mechanisms used in cancer to escape immune response. Through immune checkpoints, which are cell surface molecules involved in the immune system control,
Quentin Lemasson   +7 more
doaj   +2 more sources

Regulatory T cells infiltrate the tumor-induced tertiary lymphoïd structures and are associated with poor clinical outcome in NSCLC

open access: yesCommunications Biology, 2022
Regulatory T cells (Tregs) have similar immune profiles in tertiary lymphoid structures of lung cancer and non-TLS areas, with tumor-infiltrating Tregs found to inhibit the proliferation and cytokine secretion of CD4 + conventional T cells.
Priyanka Devi-Marulkar   +15 more
doaj   +1 more source

Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments

open access: yesMolecular Cancer, 2023
The malignant tumor is a multi-etiological, systemic and complex disease characterized by uncontrolled cell proliferation and distant metastasis. Anticancer treatments including adjuvant therapies and targeted therapies are effective in eliminating ...
Zhen-Nan Yuan   +8 more
semanticscholar   +1 more source

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

open access: yesNature Microbiology, 2022
Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron (B.1.1.529), the fifth VOC
B. Willett   +40 more
semanticscholar   +1 more source

EBV‐positive B‐cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency

open access: yesCancer Medicine, 2021
Background Epstein‐Barr virus (EBV) is detected in a variety of B‐cell lymphomas (BCLs) and B‐cell lymphoproliferative disorders (B‐LPDs). Immunodeficiency has been considered to play a key role in the pathogenesis of these diseases.
Akira Satou, Shigeo Nakamura
doaj   +1 more source

The role of lysosomal peptidases in glioma immune escape: underlying mechanisms and therapeutic strategies

open access: yesFrontiers in Immunology, 2023
Glioblastoma is the most common primary malignant tumor of the central nervous system, which has the characteristics of strong invasion, frequent recurrence, and rapid progression.
Hao Liu   +19 more
doaj   +1 more source

Timing of immune escape linked to success or failure of vaccination. [PDF]

open access: yesPLoS ONE, 2010
Successful vaccination against HIV should limit viral replication sufficiently to prevent the emergence of viral immune escape mutations. Broadly directed immunity is likely to be required to limit opportunities for immune escape variants to flourish. We
Jeanette C Reece   +9 more
doaj   +1 more source

Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC Axis and PD-L1 phosphorylation

open access: yesMolecular Cancer, 2023
Background Targeted drugs are not quite effective for prolonging the survival of patients with gastric cancer due to off-target effects as well as tumor immune escape mechanisms.
Z. Miao   +9 more
semanticscholar   +1 more source

The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape

open access: yesCell Communication and Signaling, 2023
Background Breast cancer (BC) is the second most frequent type of cancer in the world and most common among women, configuring a major challenge to global health.
Diandra Zipinotti dos Santos   +9 more
semanticscholar   +1 more source

Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?

open access: yesFrontiers in Immunology, 2017
Clinical responses to anti-tumor monoclonal antibody (mAb) treatment have been regarded for many years only as a consequence of the ability of mAbs to destroy tumor cells by innate immune effector mechanisms.
Claire Deligne   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy